Seattle Genetics (SGEN) granted FDA orphan drug status for Mycois Fungoides
Tweet
Share
E-mailGet Alerts SGEN Hot Sheet
Join SI Premium – FREE
Seattle Genetics (NASDAQ: SGEN) granted FDA orphan drug status for Mycois Fungoides
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- FDA grants accelerated approval to Ultragenyx gene therapy for GSDIa
- AbbVie lung cancer drug data shows high response rates at WCLC 2026
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
